Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Corvus Pharma Com (NQ: CRVS )

8.020 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100
Open 8.020
Bid (Size) 7.260 (1)
Ask (Size) 9.000 (11)
Prev. Close 8.020
Today's Range 8.020 - 8.020
52wk Range 1.300 - 10.00
Shares Outstanding 64,257,251
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm
From Kaskela Law LLC
Via Business Wire

Performance

YTD
+355.68%
+355.68%
1 Month
-16.11%
-16.11%
3 Month
+73.03%
+73.03%
6 Month
+274.77%
+274.77%
1 Year
+398.14%
+398.14%

More News

Read More
Alcoa, Lattice Semiconductor, Stratasys And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Outlook For Corvus Pharma
Via Benzinga
Preview: Corvus Pharma's Earnings
Via Benzinga
Earnings Scheduled For November 12, 2024
Via Benzinga
An Overview of Corvus Pharma's Earnings
Via Benzinga
Stellantis, MicroStrategy, Bit Digital And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Nio Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Via Benzinga
The 2024 Millionaire’s Club: 3 Penny Stocks to Buy Now
Via InvestorPlace
CRVS Stock Earnings: Corvus Pharma Misses EPS for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
CRVS Stock Earnings: Corvus Pharma Misses EPS for Q4 2023
Via InvestorPlace
Earnings Scheduled For March 19, 2024
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Present New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals Announces Publication of Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to T Cell-Mediated Inflammatory and Immune Diseases
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter Financial Results on November 7, 2023
From Corvus Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.